Baillie Gifford & Co. Sells 4,827,438 Shares of Sana Biotechnology, Inc. $SANA

Baillie Gifford & Co. lessened its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 42.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,609,065 shares of the company’s stock after selling 4,827,438 shares during the quarter. Baillie Gifford & Co. owned about 2.48% of Sana Biotechnology worth $26,899,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in SANA. AQR Capital Management LLC boosted its stake in shares of Sana Biotechnology by 49.8% during the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock worth $963,000 after acquiring an additional 190,483 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after acquiring an additional 90,515 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Sana Biotechnology by 86.8% during the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock worth $254,000 after acquiring an additional 43,247 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Sana Biotechnology by 11.6% during the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock worth $555,000 after acquiring an additional 21,149 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of Sana Biotechnology during the 2nd quarter worth about $50,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.21 on Tuesday. Sana Biotechnology, Inc. has a twelve month low of $1.53 and a twelve month high of $6.55. The stock has a market capitalization of $856.65 million, a PE ratio of -3.31 and a beta of 2.06. The stock has a 50-day simple moving average of $3.51 and a 200 day simple moving average of $4.13.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SANA. HC Wainwright decreased their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th. Morgan Stanley reiterated an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.